title: German-Austrian recommendations for HIV-therapy in pregnancy: update May 2003.
abstract: In Germany during the past years about 200-250 HIV infected pregnant women delivered a baby per year, a number that is currently increasing. To determine the HIV-status early in pregnancy voluntary HIV-testing of all pregnant women is recommended in Germany and Austria as part of prenatal care. In those cases, where HIV infection was known during pregnancy, since 1995 the rate of vertical transmission of HIV was reduced to 1-2%. - This low transmission rate has been achieved by the combination of anti-retroviral treatment of pregnant women, elective caesarean section before onset of labor, anti-retroviral post exposition prophylaxis in the newborn and refraining from breast-feeding by the HIV infected mother. To keep pace with new results in research, approval of new anti-retroviral drugs and changes in the general treatment recommendations for HIV infected adults, in 1998 and 2001 an interdisciplinary consensus meeting was held. Gynaecologists, infectious disease specialists, pediatricians, pharmacologists, virologists and members of the German AIDS Hilfe (NGO) were participating in this conference to update the prevention strategies. A third update became necessary in 2003. The updating process was started in January 2003 and was terminated in July 2003. The guidelines provide new recommendations on the indication and the starting point for HIV-therapy in pregnancies without complications, drugs and drug combinations to be used preferably in these pregnancies and updated information on adverse effects of anti-retroviral drugs. Also the procedures for different scenarios and risk constellations in pregnancy have been specified again. - With these current guidelines in Germany and Austria the low rate of vertical HIV-transmission should be further maintained or even further lowered.
authors.affiliation: Pediatric Clinic, Mannheim University, Mannheim, Germany. bernd.buchholz@kikli.ma.uni-heidelberg.de
authors.forename: Bernd
authors.initials: B
authors.lastname: Buchholz
authors.forename: Thomas
authors.initials: T
authors.lastname: Grubert
authors.forename: Ulrich
authors.initials: U
authors.lastname: Marcus
authors.forename: Matthias
authors.initials: M
authors.lastname: Beichert
authors.forename: Andrea
authors.initials: A
authors.lastname: Gingelmaier
authors.forename: Norbert H
authors.initials: NH
authors.lastname: Brockmeyer
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D036861:Delivery, Obstetric; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006287:Health Planning Guidelines; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008403:Mass Screening; D011247:Pregnancy; D011295:Prenatal Care
chemical_list: D019380:Anti-HIV Agents